Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Aveanna Healthcare Holdings , Inc. (NASDAQ:AVAH), a healthcare services provider with a market capitalization of $1.06 billion and an impressive 117% return over the past year, recently reported significant stock sales by key stakeholders. According to InvestingPro analysis, the stock appears slightly overvalued at current levels, with volatile price movements being a notable characteristic. The transactions, detailed in a Form 4 filing, involved multiple entities associated with J.H. Whitney Capital Partners (WA:CPAP), LLC, including J.H. Whitney VII, L.P., PSA Healthcare Investment Holding LLC, JHW Iliad Holdings LLC, PSA Iliad Holdings LLC, and JHW Iliad Holdings II LLC.
The sales occurred over two days, March 18 and 19, 2025, with a total transaction value of $822,443. The shares were sold at prices ranging from $5.46 to $5.51 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted by the stockholder entities in December 2024.
Robert M. Williams, Jr., a managing member of several of the involved entities, was listed as the reporting owner. Following these sales, the entities collectively continue to hold a substantial number of shares in Aveanna Healthcare Holdings, maintaining significant involvement in the company’s ownership structure.
In other recent news, Aveanna Healthcare Holdings Inc reported a strong financial performance for the fourth quarter of 2024, with earnings per share (EPS) reaching $0.05, significantly exceeding the forecasted loss of $0.003. The company also reported revenue of $519.9 million, surpassing the anticipated $499.07 million. This robust performance reflects Aveanna’s strategic focus on enhancing service offerings and expanding payer agreements. In another development, UBS updated its price target for Aveanna Healthcare to $4.50, up from the previous $3.20, while maintaining a Sell rating on the company’s shares. UBS’s analyst AJ Rice highlighted concerns despite the raised target, suggesting a cautious approach to Aveanna’s stock. Furthermore, Aveanna’s full-year 2024 revenue was reported at $2.024 billion, marking a 6.8% increase year-over-year. The company’s adjusted EBITDA for Q4 was $55.2 million, up 42.6% year-over-year, demonstrating effective operational strategies. Looking ahead, Aveanna projects its 2025 revenue to be between $2.100 billion and $2.120 billion, with adjusted EBITDA expected to range from $190 million to $194 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.